J&J Executive Shuffle: New CFO, Medical Devices Chair Departs

Ticker: JNJ · Form: 8-K · Filed: 2024-08-26T00:00:00.000Z

Sentiment: neutral

Topics: executive-changes, leadership, board-of-directors

Related Tickers: JNJ

TL;DR

J&J's CFO is changing Sept 3rd, McEvoy out as Med Devices Chair. Board adds new directors.

AI Summary

Johnson & Johnson announced on August 26, 2024, changes in its executive leadership, including the appointment of Thong Q. Nguyen as Executive Vice President, Chief Financial Officer, effective September 3, 2024. The company also reported the departure of Ashley McEvoy as Executive Vice President, Chairman of Medical Devices, and the election of new directors to its Board. These changes are part of the company's ongoing governance and operational adjustments.

Why It Matters

Changes in key executive positions like CFO and division leadership can signal shifts in financial strategy or operational focus, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Executive changes, especially at the CFO level, can introduce uncertainty regarding future financial strategies and operational direction.

Key Players & Entities

FAQ

Who is the new Chief Financial Officer of Johnson & Johnson?

Thong Q. Nguyen has been appointed as the new Executive Vice President, Chief Financial Officer, effective September 3, 2024.

Who has departed from their role as Chairman of Medical Devices?

Ashley McEvoy has departed from her role as Executive Vice President, Chairman of Medical Devices.

When is the effective date for the new CFO?

The appointment of Thong Q. Nguyen as CFO is effective September 3, 2024.

What other significant changes were reported on August 26, 2024?

The filing also reports the election of new directors to Johnson & Johnson's Board.

What is the standard industrial classification for Johnson & Johnson?

Johnson & Johnson's Standard Industrial Classification is Pharmaceutical Preparations [2834].

From the Filing

0000200406-24-000079.txt : 20240826 0000200406-24-000079.hdr.sgml : 20240826 20240826162620 ACCESSION NUMBER: 0000200406-24-000079 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240826 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240826 DATE AS OF CHANGE: 20240826 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 241241712 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 8-K 1 jnj-20240826.htm 8-K jnj-20240826 0000200406 false 0000200406 2024-08-26 2024-08-26 0000200406 us-gaap:CommonStockMember 2024-08-26 2024-08-26 0000200406 jnj:A5.50NotesDue2024Member 2024-08-26 2024-08-26 0000200406 jnj:A1.150NotesDueNovember2028Member 2024-08-26 2024-08-26 0000200406 jnj:A3.20NotesDueNovember2032Member 2024-08-26 2024-08-26 0000200406 jnj:A1.650NotesDue2035Member 2024-08-26 2024-08-26 0000200406 jnj:A3.350NotesDueNovember2036Member 2024-08-26 2024-08-26 0000200406 jnj:A3.550NotesDueNovember2044Member 2024-08-26 2024-08-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported):  August 26, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) One Johnson & Johnson Plaza , New Brunswick , New Jersey    08933   (Address of Principal Executive Offices)  (Zip Code)  Registrant's telephone number, including area code: 732 - 524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 5.50% Notes Due November 2024 JNJ24BP New York Stock Exchange 1.150% Notes Due November 2028 JNJ28 New York Stock Exchange 3.20% Notes Due November 2032 JNJ32 New York Stock Exchange 1.650% Notes Due May 2035 JNJ35 New York Stock Exchange 3.350% Notes Due November 2036 JNJ36A New York Stock Exchange 3.550% Notes Due November 2044 JNJ44 New York Stock Exchange Item 5.02 Departure of Directors

View on Read The Filing